AKT-mTOR signaling-mediated rescue of PRKAG2 R302Q mutant-induced familial hypertrophic cardiomyopathy by treatment with β-adrenergic receptor (β-AR) blocker metoprolol | Zendy

Jian Zhuo | Zendy; Hai-Hua Geng | Zendy; Xiaohui Wu | Zendy; Mengkang Fan | Zendy; Hongzhuan Sheng | Zendy; Jian Yao | Zendy

Open Access

AKT-mTOR signaling-mediated rescue of PRKAG2 R302Q mutant-induced familial hypertrophic cardiomyopathy by treatment with β-adrenergic receptor (β-AR) blocker metoprolol

Author(s) -

Jian Zhuo,

Hai-Hua Geng,

Xiaohui Wu,

Mengkang Fan,

Hongzhuan Sheng,

Jian Yao

Publication year - 2022

Publication title -

cardiovascular diagnosis and therapy

Language(s) - English

Resource type - Journals

eISSN - 2223-3660

pISSN - 2223-3652

DOI - 10.21037/cdt-22-81

Subject(s) - ampk , protein kinase b , pi3k/akt/mtor pathway , metoprolol , protein kinase a , phosphorylation , medicine , signal transduction , endocrinology , cancer research , microbiology and biotechnology , biology

Protein kinase AMP-activated non-catalytic subunit gamma 2 gene ( PRKAG2 ) cardiac syndrome, caused by mutations in PRKAG2 , often shows myocardial hypertrophy and abnormal glycogen deposition in cardiomyocytes. However, it remains incurable due to a lack of a management guideline for treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research